Clinical Trials Browser

Phase 1/2 × OTHER × TAK-659 × Clear all

NCT04079738 2023-09-13

Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

Phase 1/2 Terminated

8 enrolled 10 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute